Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280264 | 0.81 | MAOB (0.40) | MAOBTRPV1CYP1A2CYP2A6NPC1 | |
| SCHEMBL803417 | 0.80 | CYP1A2 (0.50) | MAOBPARP1PDE10ACYP1A2CYP2A6 | |
| SCHEMBL1695518 | 0.80 | TRPV1 (0.40) | MAOBTRPV1PDE10ACYP1A2NPC1 | |
| SCHEMBL24272452 | 0.78 | MAOB (0.38) | MAOBPARP1TRPV1PDE10A | |
| SCHEMBL14439551 | 0.78 | TERT (0.41) | CYP1A2CYP2A6NPC1RAB9ASCN10A | |
| SCHEMBL21622433 | 0.77 | PDE10A (0.50) | MAOBPARP1PDE10ACYP1A2CYP2A6 | |
| SCHEMBL14378414 | 0.77 | CYP1A2 (0.53) | TRPV1PDE10ACYP1A2NPC1RAB9A | |
| SCHEMBL6172988 | 0.76 | CYP1A2 (0.46) | MAOBPARP1PDE10ACYP1A2CYP2A6 | |
| SCHEMBL21575906 | 0.76 | TRPV1 (0.38) | TRPV1PDE10ACYP1A2NPC1RAB9A | |
| SCHEMBL29471062 | 0.76 | CYP1A2 (0.46) | MAOBPARP1PDE10ACYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141569-A1 | FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141569-A1 | FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF | DNASE1, DNA2, RNGTT | MAOB 1473/4885PARP1 279/4885TRPV1 4511/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | MAOB 902/4885PARP1 1824/4885TRPV1 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.